Methods for Assessing Mast Cell Responses to Engineered Nanomaterial Exposure

  • Nasser B. Alsaleh
  • Jared M. BrownEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1894)


Mast cells are key effector cells in inflammatory and allergic immune responses such as asthma, rhinitis, and atopic dermatitis. Activation of mast cells leads to immediate release of preformed mediators such as histamine and proteases, which can regulate vascular permeability and the function of a number of immune and nonimmune cells. Engineered nanomaterials (ENM) have been utilized for a wide range of applications and introduced into a number of consumer products; yet the consequent increase in human exposure and any potential adverse effects have not been fully evaluated. Modulation of the immune system function has been shown to be a major toxicological consequence of ENM exposure. The implication of mast cells in ENM-mediated toxicity, including the most widely utilized carbon and metal-based ENMs, has been previously demonstrated; and therefore, understanding direct ENM interaction with mast cells at the cellular and molecular level is of critical importance for the safe implementation of ENMs into consumer products.

Key words

Mast cell Degranulation Engineered nanomaterials Nanoparticles Nanotoxicity Immunotoxicity 


  1. 1.
    Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10(6):440–452. Scholar
  2. 2.
    Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6(2):135–142. Scholar
  3. 3.
    Gilfillan AM, Tkaczyk C (2006) Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6(3):218–230. Scholar
  4. 4.
    Buzea C, Pacheco II, Robbie K (2007) Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2(4):MR17–MR71CrossRefGoogle Scholar
  5. 5.
    Vance ME, Kuiken T, Vejerano EP, McGinnis SP, Hochella MF Jr, Rejeski D, Hull MS (2015) Nanotechnology in the real world: redeveloping the nanomaterial consumer products inventory. Beilstein J Nanotechnol 6:1769–1780. Scholar
  6. 6.
    Dobrovolskaia MA, McNeil SE (2007) Immunological properties of engineered nanomaterials. Nat Nanotechnol 2(8):469–478. Scholar
  7. 7.
    Dobrovolskaia MA, Shurin M, Shvedova AA (2016) Current understanding of interactions between nanoparticles and the immune system. Toxicol Appl Pharmacol 299:78–89. Scholar
  8. 8.
    Alsaleh NB, Brown JM (2017) Immune responses to engineered nanomaterials: current understanding and challenges. Curr Opin Toxicol. Scholar
  9. 9.
    Aldossari AA, Shannahan JH, Podila R, Brown JM (2015) Influence of physicochemical properties of silver nanoparticles on mast cell activation and degranulation. Toxicol In Vitro 29(1):195–203. Scholar
  10. 10.
    Chen EY, Garnica M, Wang YC, Mintz AJ, Chen CS, Chin WC (2012) A mixture of anatase and rutile TiO(2) nanoparticles induces histamine secretion in mast cells. Part Fibre Toxicol 9:2. Scholar
  11. 11.
    Katwa P, Wang X, Urankar RN, Podila R, Hilderbrand SC, Fick RB, Rao AM, Ke PC, Wingard CJ, Brown JM (2012) A carbon nanotube toxicity paradigm driven by mast cells and the IL-(3)(3)/ST(2) axis. Small 8(18):2904–2912. Scholar
  12. 12.
    Wingard CJ, Walters DM, Cathey BL, Hilderbrand SC, Katwa P, Lin S, Ke PC, Podila R, Rao A, Lust RM, Brown JM (2011) Mast cells contribute to altered vascular reactivity and ischemia-reperfusion injury following cerium oxide nanoparticle instillation. Nanotoxicology 5(4):531–545. Scholar
  13. 13.
    Alsaleh NB, Persaud I, Brown JM (2016) Silver nanoparticle-directed mast cell degranulation is mediated through calcium and PI3K signaling independent of the high affinity IgE receptor. PLoS One 11(12):e0167366. Scholar
  14. 14.
    U.S. Food and Drug Administration (2015) FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol).
  15. 15.
    Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216(2–3):106–121. Scholar
  16. 16.
    Marshall JS (2004) Mast-cell responses to pathogens. Nat Rev Immunol 4(10):787–799. Scholar
  17. 17.
    Schwartz LB (1994) Mast cells: function and contents. Curr Opin Immunol 6(1):91–97CrossRefGoogle Scholar
  18. 18.
    Yin Y, Bai Y, Olivera A, Desai A, Metcalfe DD (2017) An optimized protocol for the generation and functional analysis of human mast cells from CD34+ enriched cell populations. J Immunol Methods 448:105–111. Scholar
  19. 19.
    Maeyama K, Hohman RJ, Metzger H, Beaven MA (1986) Quantitative relationships between aggregation of IgE receptors, generation of intracellular signals, and histamine secretion in rat basophilic leukemia (2H3) cells. Enhanced responses with heavy water. J Biol Chem 261(6):2583–2592PubMedGoogle Scholar
  20. 20.
    Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454(7203):445–454. Scholar
  21. 21.
    Farre M, Gajda-Schrantz K, Kantiani L, Barcelo D (2009) Ecotoxicity and analysis of nanomaterials in the aquatic environment. Anal Bioanal Chem 393(1):81–95. Scholar
  22. 22.
    Hartmann NB, Jensen KA, Baun A, Rasmussen K, Rauscher H, Tantra R, Cupi D, Gilliland D, Pianella F, Riego Sintes JM (2015) Techniques and protocols for dispersing nanoparticle powders in aqueous media-is there a rationale for harmonization? J Toxicol Environ Health B Crit Rev 18(6):299–326. Scholar
  23. 23.
    Wittmaack K (2011) Excessive delivery of nanostructured matter to submersed cells caused by rapid gravitational settling. ACS Nano 5(5):3766–3778. Scholar
  24. 24.
    Kroll A, Pillukat MH, Hahn D, Schnekenburger J (2012) Interference of engineered nanoparticles with in vitro toxicity assays. Arch Toxicol 86(7):1123–1136. Scholar
  25. 25.
    Monteiro-Riviere NA, Inman AO, Zhang LW (2009) Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol 234(2):222–235. Scholar
  26. 26.
    Ong KJ, MacCormack TJ, Clark RJ, Ede JD, Ortega VA, Felix LC, Dang MK, Ma G, Fenniri H, Veinot JG, Goss GG (2014) Widespread nanoparticle-assay interference: implications for nanotoxicity testing. PLoS One 9(3):e90650. Scholar
  27. 27.
    Jingkun Jiang GO, Biswas P (2009) Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. J Nanopart Res 11(1):77–89CrossRefGoogle Scholar
  28. 28.
    Love SA, Maurer-Jones MA, Thompson JW, Lin YS, Haynes CL (2012) Assessing nanoparticle toxicity. Annu Rev Anal Chem 5:181–205. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, Colorado Center for Nanomedicine and Nanosafety, Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of ColoradoAuroraUSA

Personalised recommendations